New chemo combo shows promise for head and neck cancer before surgery

NCT ID NCT05294900

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tested two chemotherapy drugs, paclitaxel and carboplatin, given before surgery to 79 people with locally advanced head and neck cancer. The goal was to see how well the drugs shrink tumors before surgery. The main measure was a major pathologic response, meaning 10% or fewer cancer cells left in the tumor after treatment. The study aims to find a less toxic alternative to standard chemotherapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
paclitaxel and carboplatin (chemotherapy drugs)
What this could lead to
If successful, this could offer a less toxic chemotherapy option before surgery for head and neck cancer, potentially improving survival and reducing side effects.
What could go wrong
This is a small, early-phase trial (79 participants) with no comparison group. Results may not apply to all patients, and the treatment may still cause significant side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

head and neck squamous cell carcinoma Squamous Cell Carcinoma of Head and Neck

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Yonsei University Health System, Severance Hospital

    Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.